Siglec-2 Is a Key Molecule for Immune Response

  • Takeshi Tsubata


Siglecs are sialic acid-binding membrane-bound lectins expressed on various hematopoietic cells (Varki and Angata 2006). Siglec-2 (also called as CD22) specifically recognizes α2.6 sialic acid-containing glycans and is expressed on B cells, the precursors of antibody secreting cells, plasma cells (Nitschke and Tsubata 2004). Both biochemical analysis on various B cells and studies using Siglec-2-deficient mice have demonstrated that Siglec-2 negatively regulates signaling through the B cell antigen receptor (BCR), which plays a crucial role in response of B cells to antigen stimulation. B cells express membrane-bound immunoglobulin (Ig) as BCR. Ligation of BCR by antigens activates BCR-associated kinases, which in turn phosphorylate various substrates, leading to activation of various signaling cascades including Ca2+ signaling. Siglec-2 negatively regulates BCR signaling by recruitment and activation of SH2-containing phosphatase 1 (SHP-1), which counteracts the phospharylation-mediated activation of signaling molecules by dephosphorylation, and reduces Ca2+ signaling by regulating the activity of the Ca2+ pump PMCA. In the past few years, we have assessed the immunological function of Siglec-2 and found that it functions as a molecular switch that determines the fate of antigen-interacted B cells whether they undergo apoptosis or activation. Siglec-2 may therefore play a key role in the establishment and maintenance of normal humoral immunity, which produces antibodies to pathogens but not self-antigens, and, after vaccination, respond to pathogens rapidly.


Signal Regulation Antigen Stimulation Previous Infection Cell Antigen Receptor Antibody Secreting Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Garside P, Ingulli E, Merica RR, Johnson JG, Noelle RJ, Jenkins MK (1998) Visualization of specific B and T lymphocyte interactions in the lymph node. Science 281:96–99PubMedCrossRefGoogle Scholar
  2. Hokazono Y, Adachi T, Wabl M, Tada N, Amagasa T, Tsubata T (2003) Inhibitory coreceptors activated by antigens but not by anti-Ig heavy chain antibodies install requirement of costimulation through CD40 for survival and proliferation of B cells. J Immunol 171:1835–1843PubMedGoogle Scholar
  3. Nitschke L, Tsubata T (2004) Molecular interactions regulate BCR signal inhibition by CD22 and CD72. Trends Immunol 25:543–550PubMedCrossRefGoogle Scholar
  4. Sato M, Adachi T, Tsubata T (2007) Augmentation of signaling through BCR containing IgE but not that containing IgA due to lack of CD22-mediated signal regulation. J Immunol 178:2901–2907PubMedGoogle Scholar
  5. Varki A, Angata T (2006) Siglecs—the major subfamily of I-type lectins. Glycobiology 16:1R–27RPubMedCrossRefGoogle Scholar
  6. Wakabayashi C, Adachi T, Wienands J, Tsubata T (2002) A distinct signaling pathway used by the IgG-containing B cell antigen receptor. Science 298:2392–2395PubMedCrossRefGoogle Scholar

Copyright information

© Springer 2008

Authors and Affiliations

  • Takeshi Tsubata
    • 1
  1. 1.Laboratory of Immunology, School of Biomedical ScienceTokyo Medical and Dental University; CREST, JSTTokyoJapan

Personalised recommendations